Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Xponance Inc.

Xponance Inc. lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 5.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 65,318 shares of the biotechnology company’s stock after selling 3,454 shares during the period. Xponance Inc.’s holdings in Exelixis were worth $1,567,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Alaska Permanent Fund Corp raised its position in shares of Exelixis by 1.5% during the 3rd quarter. Alaska Permanent Fund Corp now owns 40,855 shares of the biotechnology company’s stock worth $893,000 after acquiring an additional 596 shares in the last quarter. Fifth Third Bancorp raised its position in shares of Exelixis by 44.2% during the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 604 shares in the last quarter. Signaturefd LLC raised its position in shares of Exelixis by 17.1% during the 3rd quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 668 shares in the last quarter. Treasurer of the State of North Carolina raised its position in shares of Exelixis by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 145,343 shares of the biotechnology company’s stock worth $3,176,000 after acquiring an additional 738 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Exelixis by 1.7% during the 3rd quarter. Victory Capital Management Inc. now owns 56,321 shares of the biotechnology company’s stock worth $1,231,000 after acquiring an additional 927 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

EXEL has been the topic of several research analyst reports. William Blair reissued an “outperform” rating on shares of Exelixis in a research report on Friday, January 26th. JMP Securities restated a “market outperform” rating and set a $27.00 price target on shares of Exelixis in a research note on Wednesday, April 10th. Royal Bank of Canada raised their price target on Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Stifel Nicolaus raised their price target on Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Friday, February 2nd. Finally, Barclays downgraded Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price target on the stock. in a research note on Thursday, April 11th. Six investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and an average price target of $26.29.

Exelixis Trading Up 1.8 %

Shares of EXEL stock opened at $23.29 on Wednesday. The business’s 50 day moving average is $22.61 and its two-hundred day moving average is $22.15. Exelixis, Inc. has a twelve month low of $18.08 and a twelve month high of $24.34. The company has a market capitalization of $6.87 billion, a P/E ratio of 36.39, a price-to-earnings-growth ratio of 0.60 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. The firm had revenue of $479.65 million for the quarter, compared to the consensus estimate of $481.23 million. As a group, equities analysts predict that Exelixis, Inc. will post 1.21 earnings per share for the current fiscal year.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 47,020 shares of Exelixis stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now directly owns 384,866 shares in the company, valued at $8,255,375.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Exelixis news, Director David Edward Johnson acquired 190,000 shares of the stock in a transaction dated Wednesday, February 21st. The stock was acquired at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the transaction, the director now directly owns 1,100,730 shares in the company, valued at $22,785,111. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Patrick J. Haley sold 47,020 shares of Exelixis stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the completion of the sale, the executive vice president now directly owns 384,866 shares of the company’s stock, valued at approximately $8,255,375.70. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.